Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Skin Swab Research Identifies Metabolic Changes Linked to Parkinson’s Disease

By LabMedica International staff writers
Posted on 16 Nov 2026

Parkinson’s disease can be difficult to diagnose before movement symptoms appear, highlighting the need for earlier detection methods. More...

Researchers have explored whether metabolic changes in sebum, the oily substance that protects the skin, could provide measurable indicators of the disease. Inspired by observations of a distinctive odor in people with Parkinson’s, researchers have developed a skin swab approach that identifies a chemical signature associated with the condition.

Researchers at the University of Manchester developed a skin swab method in collaboration with the Manchester Institute of Biotechnology, the University of Edinburgh, Salford Royal, Wythenshawe Hospital, SebOMIX, Parkinson’s UK, and the Defence Science and Technology Laboratory. The approach uses simple swabs to collect sebum from oil-rich areas of the skin, followed by mass spectrometry to identify and quantify molecules that may provide biological signatures associated with Parkinson’s disease.

The research began after Joy Milne, a retired nurse with hyperosmia, or a heightened sense of smell, noticed a distinctive odor in people with Parkinson’s disease. In an initial blinded study using T-shirts, she correctly identified samples from people with Parkinson’s disease and observed that the odor was strongest in sebum-rich areas, particularly the back of the neck and between the shoulders. Notably, one participant initially classified as a healthy control whom she identified by the distinctive odor was later diagnosed with Parkinson’s.

The skin swab method can detect about 15,000 molecular features, with approximately 10% consistently differing in abundance between people with and without Parkinson’s. Researchers identified a distinct chemical signature that included changes in lipid metabolism and essential amino acids. The team has now sampled more than 7,000 participants worldwide and consistently detected the signature across different ages, ethnicities, and sampling locations.

SebOMIX is seeking investment for a Greater Manchester trial that would include about 400 people with suspected Parkinson’s referred by general practitioners and about 400 people with other symptoms such as dementia. Wythenshawe Hospital clinical biochemists would analyze blinded swabs with the Manchester Institute of Biotechnology team. If the clinical laboratory reproduces the research findings, the results would support regulatory approval and laboratory accreditation processes involving the MHRA and UKAS.

“We now want to translate this lab-based diagnostic into something that can be used routinely in clinic to diagnose and better understand this awful condition,” said Professor Perdita Barran, who leads the Michael Barber Center for Collaborative Mass Spectrometry at the Manchester Institute of Biotechnology.

Related Links
University of Manchester
Manchester Institute of Biotechnology


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Unlike conventional molecular methods, VedaBio\'s CRISPR-based technology detects targets without requiring amplification (Photo courtesy of Veda Bio)

Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes

Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.